thyroid cancer

Showing 8 posts of 8 posts found.

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

August 23, 2023
Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …

novartis_side_building

FDA approves Novartis combo in rare thyroid cancer subtype

May 8, 2018
Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer

The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …

NICE recommends thyroid cancer drug trio for NHS use

February 20, 2018
Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer

NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …

eisa0002

Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England

August 2, 2016
Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer

Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …

Caprelsa image

Caprelsa approved in Europe for thyroid cancer

February 21, 2012
Sales and Marketing AstraZeneca, Caprelsa, FDA, RET, thyroid cancer

The European Commission has approved AstraZeneca’s thyroid cancer pill Caprelsa. Caprelsa (vandetanib) is now available in Europe for the treatment …

Zactima extends progression free survival in other thyroid cancers

September 13, 2010
Research and Development thyroid cancer, zactima

New data suggests patients with the more common forms of thyroid cancer respond to AstraZeneca’s Zactima. The drug has already …

ASCO

ASCO 2010: The Hedgehog Pathway and other ways to target cancer

August 19, 2010
Research and Development ASCO, Cancer, thyroid cancer

The American Society of Clinical Oncology conference, one of the most important dates in the pharmaceutical industry’s calendar, took place …

Zactima promising in rare thyroid cancer

June 11, 2010
Research and Development, Sales and Marketing AstraZeneca, thyroid cancer, zactima

AstraZeneca’s Zactima (vandetanib) will be filed with regulators later this year as a treatment for thyroid cancer after promising results. …

Latest content